BTSG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BrightSpring Health Services Inc (BTSG) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, consistent analyst upgrades, and positive growth projections outweigh the lack of recent news or significant trading trends. The technical indicators also suggest a bullish trend, making this a solid entry point for long-term growth.
The MACD is positive and contracting, indicating bullish momentum. RSI is neutral at 62.522, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 45.059, and resistance is at 48.006, with the stock currently trading near the pivot point of 46.533.
Analysts have consistently raised price targets, with the most recent targets ranging from $52 to $60, reflecting strong confidence in the company's growth potential.
The company projects 15%-20% organic EBITDA CAGR for 2026-2028, supported by historical growth rates of 18%-19%.
Q4 2025 financials show a 29.26% YoY revenue increase and a 381.78% YoY net income increase, indicating strong operational performance.
Gross margin dropped by 5.76% YoY in Q4 2025, which could indicate cost pressures.
Options data shows a higher put volume compared to call volume (Put-Call Ratio=2.38), suggesting bearish sentiment in the short term.
In Q4 2025, revenue increased by 29.26% YoY to $3.55 billion, net income surged by 381.78% YoY to $77.08 million, and EPS rose by 325% YoY to $0.34. However, gross margin dropped by 5.76% YoY to 11.62%.
Analysts are highly optimistic, with multiple firms raising price targets recently. UBS, Mizuho, TD Cowen, and others have set targets between $52 and $60, maintaining Buy or Outperform ratings. Analysts highlight strong growth prospects, business diversification, and attractive EBITDA growth projections.
